Replies to post #147090 on Biotech Values

[mcbio]

Sorry - I must not have been clear in my posting. I was saying there is the risk in this pain indication of the same issue as happened in RA (loss of efficacy over time) showing up here too. Hence I was agreeing they need to run a longer trial.

So we are on the same page here.

FWIW, and I'm not discounting the need for more LT data (for both efficacy and safety reasons), ARRY's prior 797 trial in ankylosing spondylitis tested the drug out to, and showed durability on pain to, 85 days (~16 minute mark of today's CC). Obviously that doesn't mean the effect can't wane beyond 85 days; we'll just need more data.